InvestorsHub Logo
Followers 44
Posts 6314
Boards Moderated 0
Alias Born 05/17/2014

Re: CrazyBro post# 17966

Saturday, 09/24/2016 8:45:33 AM

Saturday, September 24, 2016 8:45:33 AM

Post# of 29174
This was floating around another SL forum.


Hi XXXXXXX,

Thank you for your inquiry and I’m glad to hear you’re a Supreme shareholder. Here are my answers to your inquiries:

The investors you speak of are correct in saying that Health Canada requires two separate crops / batches be produced and submitted before a sales license will be granted. As a hedge against time delays, we have grown both our crops simultaneously to avoid another 10/12 week growing cycle so that we are ready to submit as soon as possible. I can tell you that both of those crops are now complete and will be submitted for third party lab testing before being sent to Health Canada in the coming weeks.

As for your question as to whether or not we will receive the license based on those crops, it is Health Canada’s decision at the end of the day and for that reason, I cannot guarantee we will receive the sales license from the said batches. That being said, I believe the plants are receiving the Hybrid Greenhouse model very well and you can judge for yourself from the online social media pictures from sources such as Lift. Whats more, is that we have already effectively pre-sold all of our anticipated 2016 production to 6 other Licensed Producers (contingent on reaching the appropriate regulatory approvals i.e. sales license) who believe that our product quality will meet their standards and hopefully, exceed them.

In addition, as a result of our summer non-brokered private placement which raised approximately $14.95M, the company is in a healthy cash position and fully funded for the expansion of our Phase 1. This expansion brings on an additional 80,000 sq. ft. of growing area that we anticipate to be completed early Q1 2017. The new growing area is estimated to produce approximately 10,000 kg’s of dried cannabis per annum (10,000,000 grams) representing significant growth and potential revenue for the company.

We look forward to keeping our shareholders updated as we execute on our anticipate milestones and thank you again for reaching out, do let me know if you have any other questions.

Best,
Zach Stadnyk
Corporate Finance
Supreme Pharmaceuticals Inc. SL - CSE Tel: 416-630-7272
Mobile: 519-385-1446
Email: zach@supreme.ca
Website: www.supreme.ca
Address: Suite 202 - 20 De Boers Dr., Toronto, On. M3J 0H1


THIS IS MY SIGNATURE

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.